TrialEpilepsia2022

Intravenous ganaxolone for the treatment of refractory status epilepticus: Results from an open-label, dose-finding, phase 2 trial.

Henrikas Vaitkevicius et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.